SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.

Mesa, Ruben A

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis. [electronic resource] - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Dec 2017 - 3844-3850 p. digital

Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial

1527-7755

10.1200/JCO.2017.73.4418 doi


Aged
Benzamides--administration & dosage
Disease-Free Survival
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Female
Humans
Janus Kinase Inhibitors--administration & dosage
Male
Maximum Tolerated Dose
Middle Aged
Nitriles
Patient Safety
Primary Myelofibrosis--drug therapy
Prognosis
Pyrazoles--administration & dosage
Pyrimidines--administration & dosage
Retreatment
Risk Assessment
Survival Analysis